​

Diabetes mellitus is a group of diseases characterized by high levels of blood glucose. It results from defects in insulin secretion, insulin action, or both. Diabetes can be associated with serious complications and premature death, but people having diabetes can take measures to reduce the likelihood of such occurrences.

​

Today, it is estimated that around two hundred million people globally have diabetes as compared to a global estimate of one hundred and thirty five million people with diabetes in 1995, based upon the World Health Organization estimates.

​

It is estimated that about five percent of the U.S. population in the twenty to eighty year age bracket has diabetes mellitus. The indirect and direct costs of diabetes care in the U.S. are $130 billion annually.

​

The Diabetes Atlas 2000 reconfirms the fact that type 2 diabetes constitutes about ninety five percent of all diabetes in developed countries and accounts for an even higher percentage in developing countries. The epidemic nature of diabetes continues to affect ever increasing numbers of people around the world while public awareness remains low. There are 16 million diabetics in the U.S. of which one-third are undiagnosed. In addition, there are a further twenty million Americans with impaired glucose tolerance who have blood glucose levels above the normal range. About eight hundred thousand new cases are diagnosed in the U.S. each year.

​

Mitochondrial DNA content in peripheral blood of Non Insulin Dependent diabetics (NIDDM) is one third lower than in healthy controls and the decline precedes the onset of clinical diabetes. Mitochondrial damage impairs insulin release and carbohydrate and fat metabolism contributing to the body mass disturbance in diabetes. Protecting mitochondrial function can prevent the emergence of clinical disease and enhance treatment of it. The Company’s technology is successful in preventing experimental models of diabetes and its efforts are particularly focused on preventing the complications of diabetes such as; heart or blood vessel disease, neuropathy, renal failure, heart attack, blindness, peripheral vascular disease requiring limb amputation and stroke.

​

When comparing the success of contemporary pharmaceuticals in reducing the incidence and mortality of heart attacks and strokes it is obvious that there is enormous need to for more efficacious medicines and disease management of diabetes to stabilize metabolism, prevent complications and thus reduce the human burden and financial cost